CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 820606654
- Phone
- (650) 331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 94 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-22 | Wong Stephanie Director | Grant or award · Stock Option (Right to Buy) | +19,111 | 19,111 | ||
| 2025-05-22 | Marks Gilbert Lynn Director | Grant or award · Stock Option (Right to Buy) | +19,111 | 19,111 | ||
| 2025-05-22 | Aziz Kabeer Director | Grant or award · Stock Optin (Right to Buy) | +19,111 | 19,111 | ||
| 2025-04-10 | Zakrzewski Joseph S Director | Grant or award | +10,523 | 145,538 | ||
| 2025-04-10 | Aziz Kabeer Director | Grant or award | +9,705 | 18,677 | ||
| 2025-04-10 | Martin Patricia A. Director | Grant or award | +3,065 | 6,231 | ||
| 2025-04-10 | Marks Gilbert Lynn Director | Grant or award | +9,705 | 41,507 | ||
| 2025-02-26 | Chanda Sanjay Chief Development Officer | Grant or award | +50,250 | 80,074 | ||
| 2025-02-26 | Chanda Sanjay Chief Development Officer | Grant or award · Stock Option (right to buy) | +100,500 | 100,500 | ||
| 2025-02-26 | Day Lucy Chief Financial Officer | Grant or award | +46,500 | 79,170 | ||
| 2025-02-26 | Day Lucy Chief Financial Officer | Grant or award · Stock Option (right to buy) | −93,000 | 93,000 | ||
| 2025-02-26 | Eizen Joshua M See Remarks | Grant or award | +58,500 | 175,172 | ||
| 2025-02-26 | Eizen Joshua M See Remarks | Grant or award · Stock Option (right to buy) | +117,000 | 117,000 | ||
| 2025-02-26 | Easom Eric Chief Executive Officer | Grant or award | +145,250 | 246,380 | ||
| 2025-02-26 | Easom Eric Chief Executive Officer | Grant or award · Stock Option (right to buy) | +290,500 | 290,500 | ||
| 2025-02-26 | Prior Stephen David Chief Strategy Officer | Grant or award | +28,000 | 61,313 | ||
| 2025-02-26 | Prior Stephen David Chief Strategy Officer | Grant or award · Stock Option (right to buy) | +56,000 | 56,000 | ||
| 2025-01-03 | Day Lucy Chief Financial Officer | Sale | −2,957 | $1.34 | $4K | 32,670 |
| 2025-01-03 | Chanda Sanjay Chief Development Officer | Sale | −2,957 | $1.34 | $4K | 29,824 |
| 2025-01-03 | Prior Stephen David Chief Strategy Officer | Sale | −2,029 | $1.34 | $3K | 33,313 |
Page 8 of 10 · 191 trades